Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 25 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
 


 

 
     
    Advanced search
 

 
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  


    References

 Article Access Statistics
    Viewed812    
    Printed29    
    Emailed0    
    PDF Downloaded66    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO EDITOR  
Year : 2012  |  Volume : 54  |  Issue : 3  |  Page : 293
NSAID induced hypomania in stable bipolar disorder


Department of Psychiatry, Dayanand Medical College & Hospital, Ludhiana, Punjab, India

Click here for correspondence address and email

Date of Web Publication15-Oct-2012
 

How to cite this article:
Mahajan NS, Mahajan R, Mittal R. NSAID induced hypomania in stable bipolar disorder. Indian J Psychiatry 2012;54:293

How to cite this URL:
Mahajan NS, Mahajan R, Mittal R. NSAID induced hypomania in stable bipolar disorder. Indian J Psychiatry [serial online] 2012 [cited 2019 Oct 14];54:293. Available from: http://www.indianjpsychiatry.org/text.asp?2012/54/3/293/102452


Sir,

Some case reports have proposed the antidepressant role of the non-steroidal anti- inflammatory drugs. These effects might reflect the activation syndrome [1] induced by these agents.

We describe three patients of bipolar mood disorder currently in remission as per the DSM-IV criterion who were on treatment with mood stabilizers (lithium carbonate/sodium valproate). Patients experienced pain due to neuromuscular conditions and were advised treatment with NSAIDs (nimesulide/etoricoxib/celecoxib). While on treatment, they developed symptoms of hypomania. The symptoms were seen within 3 days of the administration of the agent and remitted when the NSAIDs were stopped. Symptoms reappeared with the drug rechallenge and disappeared within 2 days of drug discontinuation. All patients stabilized after that and did not restart the NSAID. Can NSAIDs induce transient reproducible hypomanic symptoms in certain vulnerable patients with history of mood disorders?

Another possible explanation for the phenomenon could be the effect of NSAIDs on substance P (SP), which has a proven role in anxiety and nociception and acts through the activation of NK1R [2] (neurokinin 1 receptor).

SP and NK1R might play an important role in the modulation of stress-related, affective and/or anxious behavior as they are expressed in brain regions that are involved in stress, fear, and affective responses. The SP content in these areas is affected by stressful stimuli and can thus alter these states. [2]

Monoaminergic neurons of the locus coeruleus receive SP innervations and possess NK1R and are in close apposition to NK(1)-containing cells in the dorsal raphe nucleus. The action of NK1R antagonists may result from the modulation of such brain function. [3] Antagonism or the genetic inactivation of the NK1R causes alterations in serotonin and norepinephrine neuronal transmission. [2] The systemic administration of NK1R antagonists enhances the firing rate of dopaminergic, noradrenergic, and serotonergic neurons, thereby suggesting a predominating inhibitory role of SP upon monoaminergic neurons. [3] NSAIDs and Cox-2 inhibitors are known to decrease the levels of SP and thus modulate the monoaminergic system indirectly, thereby causing an increase in monoamine levels and disinhibition. Another effect of SP could be mediated through abnormalities in the signal transduction pathways and CREB (cyclic adenosine monophosphate (cAMP) response element binding proteins). These changes have been identified in patients with mood disorders. [4]

Systematic clinical studies are needed to explain the clinical manifestations of SP and NK1 Rantagonists in the mediation of mood symptoms.

 
   References Top

1.Harada T, Sakamoto K, Ishigooka J. Incidence and predictors of activation syndrome induced by antidepressants. Depress Anxiety 2008;25:1014-9.  Back to cited text no. 1
[PUBMED]    
2.Herpfer I, Lieb K. Substance P receptor antagonists in psychiatry: Rationale for development and therapeutic potential.CNS Drugs 2005;19:275-93.  Back to cited text no. 2
[PUBMED]    
3.Adell A. Antidepressant properties of substance P antagonists: Relationship to monoaminergic mechanisms?Curr Drug Targets CNS NeurolDisord 2004;3:113-21.  Back to cited text no. 3
[PUBMED]    
4.Young LT, Bezchlibnyk YB, Chen B, Wang JF, MacQueen GM. Amygdala cyclic adenosine monophosphate response element binding protein phosphorylation in patients with mood disorders: Effects of diagnosis, suicide, and drug treatment.Biol Psychiatry.2004;55:570-70  Back to cited text no. 4
    

Top
Correspondence Address:
Navkiran S Mahajan
Department of Psychiatry, Dayanand Medical College & Hospital, Ludhiana, Punjab
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-5545.102452

Rights and Permissions




 

Top